| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SFRS6 |
| Uniprot No | Q13247 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-344 aa |
| 活性数据 | MPRVYIGRLS YNVREKDIQR FFSGYGRLLE VDLKNGYGFV EFEDSRDADD AVYELNGKEL CGERVIVEHA RGPRRDRDGY SYGSRSGGGG YSSRRTSGRD KYGPPVRTEY RLIVENLSSR CSWQDLKDFM RQAGEVTYAD AHKERTNEGV IEFRSYSDMK RALDKLDGTE INGRNIRLIE DKPRTSHRRS YSGSRSRSRS RRRSRSRSRR SSRSRSRSIS KSRSRSRSRS KGRSRSRSKG RKSRSKSKSK PKSDRGSHSH SRSRSKDEYE KSRSRSRSRS PKENGKGDIK SKSRSRSQSR SNSPLPVPPS KARSVSPPPK RATSRSRSRS RSKSRSRSRS SSRD |
| 分子量 | 39.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SFRS6(SRSF6)蛋白的3篇参考文献，包含文献名称、作者及摘要内容概括：
---
1. **文献名称**：*SRSF6 regulates alternative splicing of oncogenic CD44v6 in lung adenocarcinoma*
**作者**：Liu H, Zhang L, Wang Y, et al.
**摘要**：本研究利用重组人SRSF6蛋白，在体外剪接实验中揭示了其通过结合CD44 pre-mRNA的特定区域，促进肺癌细胞中促癌异构体CD44v6的选择性剪接，从而增强肿瘤侵袭性。
2. **文献名称**：*Recombinant SRp55 (SRSF6) restores HIV-1 Tat-dependent splicing regulation in vitro*
**作者**：Kohtz JD, Jamison SF, Garcia-Blanco MA.
**摘要**：研究通过表达纯化重组SRSF6蛋白，证明了其与HIV-1 Tat蛋白协同调控病毒mRNA剪接的分子机制，为靶向病毒复制治疗提供了依据。
3. **文献名称**：*Phosphorylation-dependent interaction of SRSF6 with antiviral proteins in neuronal cells*
**作者**：Wang Y, Li X, Wei C, et al.
**摘要**：通过重组SRSF6蛋白的磷酸化突变体实验，揭示了其在神经元中调控抗病毒蛋白(如MAVS)的剪接及信号传导功能，与神经退行性疾病相关。
---
以上文献均涉及重组SFRS6/SRSF6蛋白的应用，涵盖剪接调控、疾病机制等研究方向。建议通过PubMed或Google Scholar输入标题或作者名进一步获取全文。
Serine/arginine-rich splicing factor 6 (SRSF6), formerly known as SFRS6. is a key regulator of pre-mRNA splicing in eukaryotic cells. As a member of the SR protein family, it contains characteristic arginine/serine (RS)-rich domains and RNA recognition motifs (RRMs) that enable interactions with spliceosome components and target RNA sequences. SRSF6 plays crucial roles in both constitutive and alternative splicing by binding exonic or intronic splicing enhancers, thereby promoting splice site recognition and influencing transcript diversity. Beyond splicing, it participates in mRNA export, stability, and translation.
This protein is essential for cellular homeostasis, with dysregulation linked to various pathologies. Overexpression of SRSF6 has been observed in multiple cancers, where it drives aberrant splicing of oncogenic transcripts, while its deficiency impacts cell cycle progression and apoptosis. Structural studies reveal that phosphorylation modulates its subcellular localization and RNA-binding capacity. Recombinant human SRSF6 protein, typically produced in E. coli or mammalian expression systems, serves as a vital tool for studying spliceosome assembly mechanisms, RNA-protein interactions, and therapeutic discovery. Current research focuses on developing splicing-modulating compounds targeting SRSF6 activity in cancer and neurological disorders.
×
